Circassia Pharmaceuticals (CSSPF) Financial Statements
Circassia Pharmaceuticals Financial Overview
Circassia Pharmaceuticals's market cap is currently $366.75M. The company's EPS TTM is $0.02; its P/E ratio is 40.48; and it has a dividend yield of 2.28%. Circassia Pharmaceuticals is estimated to report earnings on March 23, 2027, and the estimated EPS forecast is $0.01. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 48.70M | $ 41.80M | $ 36.80M | $ 31.30M | $ 27.90M |
| Gross Profit | $ 29.60M | $ 30.20M | $ 26.50M | $ 22.20M | $ 19.00M |
| Operating Income | $ 10.70M | $ 7.70M | $ 4.60M | $ 1.80M | $ -4.30M |
| EBITDA | $ 14.80M | $ 12.20M | $ 8.60M | $ 15.20M | $ 3.10M |
| Net Income | $ 7.00M | $ 3.70M | $ 10.70M | $ 16.10M | $ 3.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 19.90M | $ 10.90M | $ 19.90M | $ 19.40M | $ 12.60M |
| Total Assets | $ 76.20M | $ 68.40M | $ 91.50M | $ 98.50M | $ 86.40M |
| Total Debt | $ 1.00M | $ 1.50M | $ 1.10M | $ 1.00M | $ 1.30M |
| Net Debt | $ -18.90M | $ -9.40M | $ -18.80M | $ -18.40M | $ -11.30M |
| Total Liabilities | $ 8.60M | $ 8.90M | $ 7.70M | $ 16.60M | $ 19.60M |
| Stockholders' Equity | $ 73.70M | $ 59.50M | $ 83.80M | $ 81.90M | $ 66.80M |
| Cash Flow | |||||
| Free Cash Flow | $ 15.60M | $ 16.20M | $ 11.30M | $ 6.60M | $ 1.20M |
| Operating Cash Flow | $ 15.80M | $ 17.20M | $ 11.60M | $ 6.70M | $ 1.40M |
| Investing Cash Flow | $ -1.20M | $ -1.00M | $ -300.00K | $ -100.00K | $ -200.00K |
| Financing Cash Flow | $ -5.50M | $ -25.10M | $ -10.50M | $ -500.00K | $ 4.10M |
Currency in GBP
